首页 | 本学科首页   官方微博 | 高级检索  
     

静脉溶栓治疗急性心肌梗死临床疗效观察
引用本文:温淑珍,栾树理. 静脉溶栓治疗急性心肌梗死临床疗效观察[J]. 青岛医药卫生, 2002, 0(3)
作者姓名:温淑珍  栾树理
作者单位:青岛市海慈医疗集团海慈医院 266033(温淑珍),青岛市海慈医疗集团海慈医院 266033(栾树理)
摘    要:
目的 观察急性心肌梗死溶栓治疗的有效性与安全性。方法 符合溶栓治疗条件的急性心肌梗死者100例,随机分为溶栓治疗组和常规治疗对照组,分别为51例和49例。治疗组采用尿激酶150万 U静脉滴注,30min滴完,同时给与肝素抗凝治疗。结果 梗死相关动脉的再通率溶栓治疗组为68.6%,显著高于对照组的12.2%;4周病死率治疗组为7.8%,显著低于对照组的28.6%。结论 对适宜的急性心肌梗死患者溶栓治疗是安全有效的。

关 键 词:急性心肌梗死  溶栓治疗  尿激酶

The Effects and Risks of Thrombolytic Therapy in Acute Myocardial Infarction
Wen Shuzhen,et al.. The Effects and Risks of Thrombolytic Therapy in Acute Myocardial Infarction[J]. QINGDAO Medical Journal, 2002, 0(3)
Authors:Wen Shuzhen  et al.
Affiliation:Wen Shuzhen,et al. Qingdao Haiti Hospital,Qingdao 266033
Abstract:
Objective To observe the efficacy and safety of thrombolytic therapy on patients with a-cute myocardial infarction. Methods There were 100 cases to be divided into two groups:urokinase group and routine therapy group. In urokinase group, the patients were treated with intravenous urokinase 1500000 IU over 30 minutes. Results The reperfusion rate in the infarct-related artery (IRA) was significantly higher in urokinase group than in control group (68.6% vs 12. 2%). The mortality during 4 weeks was significantly lower in urokinase group than in control group(7.8% vs 28.6%).Conclusion In the absence of contraindication,administration of intravenous urokinase to patients with acute myocardial infarction is effective and safe.
Keywords:Acute myocardial infarction Thrombolytic therapy Urokinase
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号